1. Anticancer effects of disulfiram in T-cell malignancies through NPL4-mediated ubiquitin–proteasome pathway. Issue 4 (1st April 2022) Authors: Chen, Cunte; Nie, Dingrui; Huang, Youxue; Yu, Xibao; Chen, Zheng; Zhong, Mengjun; Liu, Xin; Wang, Xianfeng; Sui, Songnan; Liu, Zhuandi; Tan, Jiaxiong; Yu, Zhi; Li, Yangqiu; Zeng, Chengwu Journal: Journal of leukocyte biology Issue: Volume 112:Issue 4(2022) Page Start: 919 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Anticancer effects of disulfiram in T‐cell malignancies through NPL4‐mediated ubiquitin–proteasome pathway. Issue 4 (1st April 2022) Authors: Chen, Cunte; Nie, Dingrui; Huang, Youxue; Yu, Xibao; Chen, Zheng; Zhong, Mengjun; Liu, Xin; Wang, Xianfeng; Sui, Songnan; Liu, Zhuandi; Tan, Jiaxiong; Yu, Zhi; Li, Yangqiu; Zeng, Chengwu Journal: Journal of leukocyte biology Issue: Volume 112:Issue 4(2022) Page Start: 919 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Disulfiram, an aldehyde dehydrogenase inhibitor, works as a potent drug against sepsis and cancer via NETosis, pyroptosis, apoptosis, ferroptosis, and cuproptosis. Issue 3 (1st July 2022) Authors: Nie, Dingrui; Chen, Cunte; Li, Yangqiu; Zeng, Chengwu Journal: Blood science Issue: Volume 4:Issue 3(2022) Page Start: 152 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. High expression of LOC541471, GDAP1, SOD1, and STK25 is associated with poor overall survival of patients with acute myeloid leukemia. (27th January 2023) Authors: Yu, Xibao; Chen, Cunte; Hu, Yanyun; Li, Kehan; Zhang, Yikai; Chen, Zheng; Nie, Dingrui; Gao, Rili; Huang, Youxue; Zhong, Mengjun; Wang, Caixia; Wang, Shunqing; Zeng, Yixin; Li, Yangqiu; Zeng, Chengwu Journal: Cancer medicine Issue: Volume 12:Number 7(2023) Page Start: 9055 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. MiR-204 suppresses the progression of acute myeloid leukemia through HGF/c-Met pathway. Issue 1 (1st January 2021) Authors: Nie, Dingrui; Ma, Ping; Chen, Yanli; Zhao, Huayan; Liu, Lin; Xin, Dao; Cao, Weijie; Wang, Fang; Meng, XiaoLi; Liu, Linxiang; Xie, Menghan; Sun, Ling Journal: Hematology Issue: Volume 26:Issue 1(2021) Page Start: 931 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗